Kurs & Likviditet
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Bioteknik |
2022-05-09 08:45:00
Oslo (Norway), 9 May 2022 - PCI Biotech (OSE: PCIB), a clinical-stage biopharma
company developing innovative therapeutics that address significant unmet
medical needs in cancer today announced a poster presentation at the TIDES USA
2022 conference, a hybrid on-site and virtual event taking place May 9-12, 2022
in Boston, USA.
Dr. Anders Høgset, CSO, will on-site present a poster named 'Photochemical
internalisation (PCI) - enhanced and site-directed mRNA delivery by light-
induced endosomal release' giving an overview of PCI Biotech's proprietary
platform technology for use in the exciting field of mRNA-based therapies. The
poster will be made available on PCI Biotech's webpage under
www.pcibiotech.no/other-presentations (http://www.pcibiotech.no/other-
presentations).
Contact information:
Per Walday, CEO
pw@pcibiotech.no (mailto:pw@pcibiotech.no)
Mobile: +47 917 93 429
About TIDES USA 2022
TIDES USA is an oligonucleotide and peptide therapeutics focused event. It is
the world's largest gathering for those interested in accelerating
oligonucleotide, peptide, mRNA and genome editing products from early discovery
to late-stage development and commercialisation.
The program features concurrent tracks covering scientific themes including in-
depth development strategies, trends, and technologies across the entire
spectrum of oligonucleotides, peptides, mRNA, and genome editing. Industry-
leading speakers share cutting-edge science and progress and scientific agenda
includes 150+ of the industry's top scientists to present the latest science and
industry updates across the entire spectrum from discovery, preclinical,
clinical development through CMC, manufacturing and commercialisation of
therapeutics and vaccines for oligos, peptides, mRNA and genome editing
products.
About PCI Biotech
PCI Biotech is a biopharmaceutical clinical stage development company focusing
on development and commercialisation of novel therapies for the treatment of
cancer through its innovative photochemical internalisation (PCI) technology
platform. PCI induces triggered endosomal release that is used to unlock the
true potential of therapeutic modalities.
The company's lead programme fimaVacc aims to enhance immunotherapy in cancer,
by triggered endosomal release of antigens or nucleic acids encoding antigens,
or immunostimulatory factors. Enhancement of relevant immune responses with
protein- and peptide-based vaccines were successfully demonstrated in humans
through an extensive Phase I study in healthy volunteers and a Phase II study is
in planning with the aim to demonstrate enhancement of immunotherapy for
treatment of solid tumours. In the fimaNAc programme endosomal release is
utilised to provide intracellular delivery of nucleic acids, such as mRNA and
RNAi therapeutics, thereby addressing one of the major bottlenecks facing this
emerging and promising field.
For further information, please visit: www.pcibiotech.com
(http://www.pcibiotech.com)
Forward-looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
PCI Biotech disclaims any obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.